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Abstract 
Candidiasis, the yeast infection of the mouth, genitals, and blood can be fatal in 
individuals who are immunocompromised. In humans, Candidiasis is  most commonly caused by 
the yeast, Candida albicans (C. albicans), but can also be caused by other Candida species .[1]  
 C. albicans demonstrates marked resistance towards Cu(II)  but  more sensitivity towards 
Co(II) compounds, especially in mutants that lack the CaCRP1 and CaCUP1 gene that encodes 
for the copper-transporting P-type ATPase and Metallothionein proteins, respectively.[2] Here, I 
will describe the effects of Co(II) and Cu(II) metal based complexes that incorporate a bridging 
pyrophosphate (PPi) moiety.  
Currently, we are exploring potential mechanisms of copper resistance and cobalt 
sensitivity in C.  albicans. We hope that in doing so, we can deepen our understanding of the 
nature of C. albicans sensitivity and shed more light on potential development of therapeutics. 
 The main focus of this report will focus on the relationship between Co(II) and Cu(II) 
during in vitro assays of C. albicans clinical isolates to measure growth and metal retention in C. 
albicans. 
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Executive Summary 
Recent years have seen a rise in fungal infections due factors such as poor patient 
adherence to long term treatment and the increasing number of patients with severe 
immunosuppression. While life expectancy has increased by more than ten years, this has also 
led to an increase in the number of fungal infections and subsequent antimicrobial resistance. 
The rise in drug resistance is currently an issue of much concern in the public world health sector 
and emphasizes the crucial need for developments of new classes of antimicrobial therapies. 
Of current fungal infections, candidiasis will be the focus of our discussion. Commonly 
caused by the opportunistic yeast, Candida albicans, candidiasis includes oropharyngeal/ 
esophageal, vulvovaginal, and invasive candidiasis which are infections of the mouth, genitals, 
and blood. Candida infections are commonly treated by azole-class drugs such as first line 
defense drugs, fluconazole and itronazole. However, the current trend in resistance to first- and 
second-line defense therapies has led our lab to explore the use of metal-based compounds as 
potential alternative antimicrobial therapeutics. We are particularly interested in the use of Co+2- 
and Cu+2- pyrophosphate (PPi) bridged complexes. 
We hypothesize that specificity for and efficacy against Candida albicans can be 
achieved by using Co+2 and Cu+2 complexes featuring the PPi moiety. We also hypothesize that 
C. albicans will demonstrate higher sensitivity towards pyrophosphate-incorporated Co+2  than to 
Cu+2 complexes due to mechanisms associated with evolution of resistance.  
 The first aim of my project was to resynthesize and character Co+2 and Cu+2 complexes, 
{[Co(phen)2]2(µ-P2O7)} (CoD) and {[Cu(phen)]2(µ-P2O7)} (CuD). My second aim was to work 
in collaboration with Dr. Michael Cynamon at the Veterans Affair Hospital (Syracuse, NY) to 
perform in vitro assays on C. albicans isolates and Saccharomyces cerevisiae. All in vitro assays 
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were done in the Cynamon group’s Biosafety Level 3 (BSL 3) facility, thus allowing us to work 
with Candida albicans, a BSL 2 organism. My third aim was to perform in vitro assays of 
mutant C. albicans strains, KC643 WT, KC2 WT, KC6 crp1Δ, KC7 crp1Δ, KC24 cup1Δ/crp1Δ, 
and KC12 cup1Δ which were kindly donated to us by Dr. Daniel Kornitzer, Technion-Israel 
Institute of Technology, Israel. These mutant strains lack the gene required to synthesize 
metallothionein (CaCUP1 gene) and the gene responsible of the P-type ATPase transporter 
protein (CaCRP1 gene).  My third goal is to perform Inductively Coupled Plasma Atomic 
Emission Spectroscopy (ICP-AES) to measure metal retention in these organisms. 
 Once CoD and CuD were synthesized, in vitro assays consisted of microtiter assays that 
determined the minimum inhibitory concentrations (MIC) in µg/mL concentrations. Mueller-
Hinton broth (MHB) was used for S. cerevisiae. S. cerevisiae contains two copper import 
transporters, Ctr1 and Ctr3, and was used as a quality control assay. 
RPMI media was initially used during the in vitro assays because it was approved by the 
Clinical and Laboratory Standard Institute (CLSI). Strains tested in RPMI were isolate #1, 
KC643 WT, and KC24 cup1Δ/crp1Δ. All strains except for S. cerevisiae were also tested in YPD 
media with uridine (KC12 cup1Δ and KC2 WT) and without (KC643 WT, KC24 cup1Δ/crp1Δ, 
KC6 crp1Δ, and KC7 crp1Δ). 
 In RPMI media, isolate #1 and KC643 demonstrated higher sensitivity towards CoD than 
towards CuD. Meanwhile, mutant, cup1Δ/crp1Δ, exhibited greater sensitivity towards CuD than 
to CoD. This aligned with our expectations because the mutant lacked both genes responsible for 
sequestering or effluxing copper ions and Co+2 should therefore be more active. In YPD media, 
the same trend is observed again. MIC values of the remaining mutants, cup1Δ and crp1Δ, shows 
that the CuD complex has higher activity than the CoD. Interestingly, crp1Δ is more sensitive 
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towards CuD than was cup1Δ. This finding further suggests that the copper extrusion pump plays 
a large role than the copper binding metallothionein in copper resistance. The double gene 
knockout mutant, cup1Δ/crp1Δ, has the lowest MIC value of all the strains, suggesting that both 
types of resistant mechanism takes part in lowering intracellular copper toxicity.  
 It should also be noted that all isolates grown in YPD media showed higher growth than 
when grown in RPMI and CoD is significantly less active. A likely explanation is that the YPD 
media contain unspecified metal chelators that diminishes the cytotoxic affect of CoD and CuD. 
Varying the media emphasizes the importance of these the types of conditions in which these 
organisms thrive. C. albicans are found in the mammalian digestive tracts where copper 
concentrations are naturally high. While copper is an essential cofactor at low concentrations, it 
becomes toxic at higher concentrations. Thus, C. albicans must have adapted to its ecological 
niche to survive. In turn, C. albicans is not naturally exposed to toxic levels of cobalt metals in 
its environment. Therefore, it has not had to opportunity to evolve mechanisms of cobalt 
resistance. 
 To help explain the possible chelating effect of YPD media, future work includes 
performing assays in MHB where extracellular metal binding is not observed. Finally, ICP-AES 
assays will be performed to further understand the behavior of intracellular copper and cobalt 
metals.   
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Introduction  
1.0) Hypothesis and Specific Aims 
 We hypothesize that specificity for and efficacy against C. albicans can be achieved by 
using Co(II) and Cu(II) complexes featuring a pyrophosphate (PPi) moiety. We also hypothesize 
that C. albicans will demonstrate higher sensitivity towards pyrophosphate-incorporated Co(II) 
complexes as compared to the copper analogues through mechanisms associated with evolution 
of resistance.   
My first aim was to synthesize and characterize the Co(II) and Cu(II) complexes that 
incorporated pyrophosphate. My second aim was to perform in vitro testing of these complexes  
against  Candida albicans, Candida krusei, Candida tropicalis, and Saccharomyces cerevisiae. 
My final aim was to perform in vitro assays on single and double gene knockout strains of C. 
albicans: KC643 WT, KC2 WT, KC6 crp1Δ, KC7 crp1Δ, KC24 cup1Δ/crp1Δ, and KC12 
cup1Δ. 
 
1.1)  Overview of Candidiasis[3] 
Candidiasis, colloquially known as “yeast infection”, is a type of fungal infection that 
occurs due to an imbalance of microorganisms at a particular location on the host and is most 
prevalent in the United States. Usually caused by the opportunistic yeast, Candida albicans of 
the Candida genus. This type of mycosis causes severe diseases in immunocompromised 
individuals which can be fatal. Oropharyngeal candidiasis, also known as ‘thrush’, is marked by 
the distinctive whitening of the tongue due to yeast overgrowth. Thrush is common in people 
undergoing immunosuppressive therapy for cancer, patients with HIV/AIDS, after antimicrobial 
therapy, or those receiving immune suppressive therapy after organ transplantation. C. albicans 
is also the pathogen involved in vaginal yeast infections. 
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Infections are diagnosed through either a microscopic examination or culturing a sample 
from the patient. During microscopic examinations, the affected area is swabbed or scraped and 
treated with potassium hydroxide (KOH). KOH dissolves the skin cells, leaving just C. albicans 
to be visualized and examined. In the culturing method, the infected area is swabbed, streaked 
onto a culture medium, incubated at 37 ˚C for several days, and the colonies are then examined. 
A  C. albicans colony is round, smooth, and white.  
C. albicans is present in healthy humans, especially in the oral and intestinal flora, and 
are in constant competition with other microorganisms for a particular location on the host. Until 
an environmental imbalance occurs, C. albicans lives  with other organisms in a commensal 
relationship. An imbalance can be caused by stressors such as changes in pH or hormones, 
oftentimes allowing C. albicans to outcompete the other organisms and overpopulate, leading to 
disease.  
 
1.4) Candida albicans and Treatment[4] 
There are five main antifungal drug classes, each with its own targets. For example, 
fluorinated pyrimidine analogs (5-FC) target the synthesis of RNA and DNA by interfering with 
DNA replication. Polyene drugs, Nystatin and Amphotericin B (AMB), have heterocyclic 
moieties that allow them to insert into the lipid bilayers of C. albican’s, increasing the cell’s 
permeability by binding to ergosterol, and forming pores. Evidence shows that polyenes cause 
oxidative damage and permit the efflux of cations, leading to cell death. 
Unlike polyenes, azoles are fungistatic meaning that growth is inhibited, and the 
organism is not killed. Fluconazole (Flu) is the azole first line of defense against C. albicans 
infections and interferes with sterol biosynthesis by inhibiting lanosterol demethylase, a key 
enzyme involved in ergosterol synthesis. Levels of ergosterol are depleted, which decreases 
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membrane integrity decreases and increases membrane permeability leading to fungal growth 
inhibition.  
Unlike earlier azole drugs such as ketoconazole, the synthetic triazole fluconazole offers 
several advantages such as increased solubility, longer plasma half-life, and improved 
pharmacokinetic properties. 
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Need for New Drug Development to Combat Drug Resistance 
2.0) Rise in Drug Resistance  
The increase in drug-, multidrug-, and extensively drug resistant bacteria and yeast 
compromises the effectiveness of existing antibiotics and antifungal treatment. In recent years, 
there has been little effort in developing new classes of broth drugs. The resistance to current 
treatments emphasizes the crucial need for new drug development, unfortunately, there are 
relatively few new antibacterial compounds undergoing development, and few new classes of 
antibacterial and antifungal drug therapy has been introduced to the market in the past three 
decades.[5] The absence of new classes of drugs highlights the difficulties in discovering and 
clinically testing new therapeutic agents.[6] 
Avenues of approach include biogenesis and examining genes thought to be directly 
involved in regulatory enzymes.[9] Researchers have also attempted to bypass bacteria such as M. 
tuberculosis’s ability to adapt by developing new analogues of established drugs and screening 
the compounds for activity using in vitro whole cell assays. As a result, private and public 
research groups focus on finding new targets for potential antibiotic compounds. However, many 
current treatments share similar or the same cellular targets, resulting in cross-resistance.[9] 
 
2.1) Drug Resistance in Candidiasis [1,6,7] 
Despite promising results from front line drugs, recent studies show that prolonged 
fluconazole treatment resulted in treatment failures and C. albicans eventually develops a higher 
resistance. It is possible that fluconazole is either not being retained (cellular uptake or efflux) or 
that the drug target (14α-sterol demethylase) has changed. It is also possible that the membrane 
composition has been altered and permeability towards fluconazole has decreased.  
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Recent studies found that at high fluconazole concentrations, the rate of accumulation 
plateaus, suggesting that the drug enters by facilitated diffusion. Additionally, there are two 
genes, BENr and the CDR1 which encodes for proteins implicated in drug resistance and ATP-
binding cassette-type transporter, respectively. Studies have also found that C. albicans isolates 
that are resistant to fluconazole also expressed high levels of BENr, while isolates that are 
resistant towards other azoles are possibly associated with elevated levels of CDR1 expression. 
While increases in CDR1 and BENr levels do not necessarily lead to increased levels of their 
products in in vitro systems, there is indirect evidence that Cdr1 and Benr multidrug transporters 
in C. albicans use azoles as substrates in drug efflux. It is also plausible that elevated levels of 
Benr and Cdr1 proteins interfere with systems that are directly involved with multidrug 
resistance. If so, this regulatory function would follow recent evidence that suggest different 
efflux systems are working together to form drug resistance mechanisms. 
 
2.2) Unusual Resistance of Candida albicans to Copper 
Interestingly, C. albicans has a high level resistance to elevated concentrations of copper, 
especially when compared to Saccharomyces cerevisiae, and previous gene disruption studies 
indicate that the copper-transporting P-type ATPase, coded by CaCRP1, is largely responsible 
for this unusual resistance. A second gene, CaCUP1 which codes for metallothionein, has also 
been implicated in copper resistance by functioning in residual copper binding. Under acidic, 
anaerobic conditions the function of CaCRP1 is crucial for survival, even in very low 
concentrations of copper.[1] 
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2.3) Metallotherapeutics: New Generation of Alternative Drugs[6] 
Despite roadblocks in finding new treatments for various forms of infectious diseases, a 
growing area in drug discovery is bioinorganic chemistry. While metal-based therapeutics make 
up a small percentage of available drugs, utilizing metals in drug delivery offers numerous 
advantages over organic-based drugs. To begin, metals are cationic which allows them to attract 
towards the negatively charged yeast cell membranes while also maintaining the metal 
center(s)’s 3D geometry and ligand arrangements. Metals can also be active in their inert, 
reactive, and biotransformational forms and metal complexes can even be active in fragmented 
parts. Thus, metallopharmaceutical complexes offer varying redox states, extensive geometrical 
diversity, and a great sum effect of metal-ligand interactions.  
 
2.4) Existing Applications of Metals in Medicinal Chemistry[8] 
After the breakthrough discovery of cisplatin, metal medicinal chemistry has become a 
point of interest with a rise in effective compounds used in treatments against diseases such as 
cancer, diabetes, and rheumatoid arthritis (RA).  
Discovered by accident, cisplatin was the first metal-based agent to be used effectively 
worldwide. A Pt(II)-based square planar compound, cisplatin can be administered alone or in 
combination with other drugs to treat various types of cancers such as ovarian, lung, and bladder. 
Cisplatin remains the ‘gold-standard’ despite the rise of second- and third-line Pt(II) analogues 
such as carboplatin and oxaliplatin. 
In treating diabetes, vanadyl complexes uses V+4 and V+5 to mimic insulin behavior by 
oxidizing glucose in adipocytes and reducing blood glucose levels. Currently, 
bis(ethylmaltolato)oxovanadium(IV), “BEOV”, is undergoing phase II  clinical trials and is 
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orally administered. Results show that patients treated with BEOV have a 15% decrease in blood 
glucose levels relative to levels before the trials.  
Aside from vanadium and platinum compounds, gold has two oxidation states that are 
found in biological conditions; Au+ and Au+3, and forms drugs, myochrysine, solganol, 
sanochrysine, and auranofin that are used to treat rheumatoid arthritis. Of these compounds, only 
myochrysine, solganol, and sanochryine are soluble and are thus injected into patients while 
auranofin is administered orally. Gold functions by targeting proteins and small molecules with 
thiols or thioether functional groups and by saturating throughout the body, accumulating most at 
sites of inflammation.  
 
2.5) Efficacy of Inorganic Pyrophosphate Complexes[9] 
We wanted to synthesize neutral dinuclear divalent compounds by using pyrophosphate 
as the hydrophilic core. In addition to pyrophosphate, the metal centers would be chelated to 
aromatic ‘capping’ ligands to create a hydrophobic component. Pyrophosphates also serve as 
excellent ‘bridging’ ligands due to their level of protonation on the ligand species. 
Pyrophosphate is a diphosphatetra-anion ([O3P-O-PO3]
4-) and plays an important role in 
bioenergetics processes. Found ubiquitously in nature the –P-O-P— moiety is a major form of 
energy bond that circulates throughout living cells. Compounds with pyrophosphate have  been 
studied extensively, especially for their roles in coordination chemistry with possible 
applications as treatment against infectious diseases. However, only 33 metallo-pyrophosphate 
complexes have been properly characterized and reported to date, and of these compounds, only 
18 complexes incorporate pyrophosphate as a bridging construct. 
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Despite the modest numbers in pyrophosphate complexes, PPi coordination chemistry 
has garnered much attention, specifically for their roles as potential drugs/prodrugs. More 
recently, research from Doyle et al. and Bose et al. have contributed to interest revolving around 
these pyrophosphate complexes as potential antitumor agents.[11,12] Work in these two labs show 
that pyrophosphate systems involving Pt(I)/Pt(IV) or dimeric Co(II)/Ni(II)/Cu(II) demonstrated 
extraordinary toxicity in drug-resistant cancer cell lines. The concentration of Pt-based 
pyrophosphate compounds of the Bose group at which 50% of  cisplatin/carboplatin-resistant 
A2780/C30 cancer cell line was inhibited (IC50 value) was approximated half that of the required 
cisplatin concentration. These complexes showed little DNA binding, suggesting that 
pyrophosphate complexes to be potential alternative anticancer agents.[10] 
Research performed in our lab utilizes and examines the added cytotoxicity of 1,10-
phenanthroline (phen) in dimeric compounds, {[Co(phen)2]2(μ-P2O7)} (CoD) and 
{[Cu(phen)]2(μ-P2O7)} (CuD). These compounds appear to have unusually high toxicity against 
Adriamycin-resistant A2780/AD cell line within the time dependent nano- and pico-molar 
toxicity range. Meanwhile, cisplatin control has an inhibitory concentration of 11µM. The 
overall toxicity is the sum of DNA interactions via binding or intercalation, oxidative stress, and 
topoisomerase I inhibition. Internationalization of these complexes remains relatively unclear, 
but a possibility is hydrolysis of the pyrophosphate upon entering and activation.[12] 
The extraordinary degree of antineoplastic activity of CoD and CuD has led the Doyle 
group to consider them as possible antibacterial therapeutics.  
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Materials and Methods 
3.0) Materials 
Candida albicans ATCC 90028 and Saccharomyces cerevisiae were purchased from the 
American Type Culture Collection (Manassas, VA) and were used as quality control strains. 
Additional isolates were obtained from the Clinical Microbiology Laboratory, SUNY Upstate 
Medical Center in Syracuse, NY Candida albicans #1 and C. albicans strains: KC643 WT, KC2 
WT, KC6 crp1Δ, KC7 crp1Δ, KC24 cup1Δ/crp1Δ, and KC12 cup1Δ were kindly donated to us 
by Dr. Daniel Kornitzer, Technion-Israel Institute of Technology, Israel. 
Susceptibility tests were performed on the isolates according to the Clinical and 
Laboratory Standard Institute (CLSI) document M27-A3 (Institute 2008). RPMI 1640 from 
Hyclone Laboratories in Logan, UT was buffered at pH=7 with MOPS, 0.165 M. The control 
drug, fluconazole (Sigma, St. Louis, MO) was made at 25.6 µg/mL in dimethyl sulfoxide. 
Finally, cell turbidity was determined by a Klett colorimeter. 
 
3.1) Synthesis {[Co(phen)2]2(µ-P2O7)} (CoD)  
CoSO4 hexahydrate (0.5622g, 2 mmol) was dissolved in 15 mL of deionized H2O 
resulting in a pale pink solution. Solid 1,10-phenanthroline (0.7208 g, 4 mmol) was next added 
to the solution and allowed to fully dissolve before adding 5mL of aqueous tetrasodium 
pyrophosphate (0.1659 g, 1 mmol) for a 2:4:1 ratio. The mixture was allowed to stir until a solid 
pale pink solution with pink precipitate formed. The supernatant and precipitate were separated 
via centrifugation and the supernatant was filtered for crystallization while the precipitate was 
dried. Crystallization was conducted through slow evaporation in 25 mL glass beakers, resulting 
in red-pink crystals after ca. 3-4 days. Crystals were also obtained through liquid-liquid 
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diffusion. This was achieved by dissolving dried precipitate in water and minimal methanol. 
Crystals formed in about 2-3 days. C54H56Co2N8O13P2 (1204.87): calculated. C 53.9, H 4.70, N 
9.30; found C 53.8, H 4.69, N 9.31. FTIR (KBr):  = 1625 (w), 1516 (s), 1497 (s), 1424 (s), 1342 
(s), 1180 (sh), 1103 (br), 1021 (s), 906 (m), 849 (s), 725 (s), 566 (w) cm–1. 
 
3.2) Synthesis of [Cu(phen)]2(μ-P2O7) (CuD) 
CuD was synthesized in a similar procedure as the synthesis of CoD. First, CuCl (0.2689 
g, 2 mmol) was dissolved in in 15 mL of deionized water to create a faint blue solution that was 
free of precipitates. Next, solid 1,10-phenanthroline (0.3604 g, 2 mmol) was added to the first 
solution. Finally, 5 mL of aqueous tetrasodium pyrophosphate (0.1659 g, 1 mmol) was added to 
the solution for a final volume of 20 mL and yielded blue solution with no precipitate. The 
solution was centrifuged at 4000 rpm for 10 minutes and the supernatant filtered out and 
crystallized via ambient conditions for approximately 3 days. FTIR (KBr):  = 1625 (w), 1516 (s), 
1497 (s), 1424 (s), 1342 (s), 1180 (sh), 1103 (br), 1021 (s), 906 (m), 849 (s), 725 (s), 566 (w) 
cm–1.  
 
3.3) Preparation of Antifungal Agents 
A dry stock solution of fluconazole was prepared in DMSO for a final concentration of 
25.6 µg/mL The CoD drug solution was prepared by dissolving 10 mg of CoD in 10mL of 
MeOH for a 1000 µg /1mL concentration. Additional CoD drug solutions were prepared at a 
final concentration of 2000 µg /1mL and 5000 µg /1mL in 10% MeOH. Two CuD drug solutions 
were prepared as well. The first was performed by adding10 mL of water to 10 mg of CoD (1000 
µg/mL) and the solution was placed in an oil bath at 80 ˚C overnight or until fully dissolved. The 
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second CoD solution was also dissolved in an oil bath, but this time the concentration was 20 mg 
of CoD in 10 mL of water (2000 µg/mL). All of the solutions were filter-sterilized before using 
in the in vitro assays. A methanol control was also used. 
 
3.4) Determining MICs and CFU of Antifungal Agents 
Saccharomyces cerevisiae was cultured and tested in Mueller Hinton Broth (MHB). 
Candida albicans isolates (ATCC 90028, isolate #1, KC643 WT, KC2 WT, KC6 crp1Δ, KC7 
crp1Δ, KC24 cup1Δ/crp1Δ, and KC12 cup1Δ) were cultured in 10 mL of media and incubated 
overnight. RPMI-MOPS was initially used for C. albicans ATCC 90028, isolate #1, KC643 WT, 
and KC24 cup1Δ/crp1Δ.  YPD(-) uridine media was used for KC643 WT, KC6 crp1Δ, and KC7 
crp1Δ. The C. albicans KC643 is the wildtype strain for the KC6 crp1Δ and KC7 crp1Δ gene 
knockout mutants.  KC2 is the wildtype strain of the cup1Δ mutant, KC12. The KC24 cup1Δ 
/crp1Δ mutant is missing both CaCUP1 and CaCRP1 genes. 
The drugs were prepared at four times the maximum concentration tested and 50 µL of 
each drug stock solution was added respectively to the first well and serially diluted two-fold, 
until the last well in which no drug was added to serve as a positive growth control. To prepare 
fungal isolates, overnight cultures were diluted to a final concentration of approximately 5 x 105 
CFU/mL in the respective broth. The actual inoculums were measured by plating and counting 
CFU on the respective agar after 1:10000 serial dilution in saline with 0.05% Tween 80. The 
agar plates were incubated for 2-4 days at 37 °C. The microtiter plates were covered with 
SealPlate adhesive film (Excel Scientific, Wrightwood, CA) and incubated at 37 °C for the same 
time period as the respective agar plates. The MIC was defined as the lowest concentration of 
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antifungal agent yielding no visible turbidity.  Each isolate was tested in at least one triplicate 
and a known antifungal was used as a positive control.  
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Results and Discussion 
4.0) Synthesis and Characterization of Compounds CoD and CuD 
The CoD compound was synthesized from an aqueous suspension of heptahydrate cobalt 
(II) sulfate, phen, and tetrasodium pyrophosphate in a 2:4:1 stoichiometric ratio, resulting in a 
pale pink solution with pink precipitate. Slow crystallization yielded pink-red crystalline blocks 
after allowing to supernatant to evaporate at room temperature. The crystals were separated from 
the remaining mother liquor, dried, and characterized by infrared spectroscopy (IR), elemental 
analysis, and ultraviolet-visible spectroscopy. Meanwhile, the Cu(II) analog was synthesized in a 
similar manner, but this time with a 2:2:1 stoichiometric ratio. The IR spectrum showed 
characteristic [P—O—P] stretches at approximately 1103 and 840 cm-1 with shoulders at 
approximately 1164 and 1021 cm-1. The presence of a phenanthroline ring was indicated by 
bands near 1517 and 1426 cm-1. Water molecules that are shown by the broad band at 
approximately 3400 cm-1 (figure 1).   
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Figure 1. (a) Infrared spectrum of CoD (b) Infrared spectrum of CuD. 
(a) (b) 
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4.1) Crystal Structures of CoD and CuD 
Single crystal X-ray diffraction 
studies of compounds CoD and CuD (see 
figure 2) show neutral species with binuclear 
cobalt(II) and copper(II) centers 
(respectively) and each metal center is 
chelated to 1,10-phenanthroline rings: two 
ligated to each cobalt(II) and one ligated to 
copper(II) ions. Additionally, each metal center is 
bridged by the hydrophilic pyrophosphate moiety 
which forms a bis-bidentate structure and forms a 
six member-chelate ring to each cobalt(II) and 
copper(II) centers. The overall geometries of CoD 
and CuD are a distorted octahedral and a 
distorted square pyramidal with water molecules 
filling in the axial positions for the copper analogue.  
The resulting structures have pseudo-layers that contain water molecules in between 
these layers. This supramolecular effect arises from a combination of intermolecular π- π 
stacking interaction between the phen ligands. 
4.2) In vitro Cell Cytotoxicity  
When S. cerevisiae demonstrated relative resistance towards both the copper dimer and 
cobalt dimer complexes, but with little variations in MIC between the two (Table 1). According 
Figure 2. (a) CoD complex (b) CuD complex 
(a) 
(b) 
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to the results, S. cerevisiae appears to be slightly more susceptible to copper than to the cobalt 
analogue. This was expected because S. cerevisiae possess two copper import proteins, Ctr1 and 
Ctr3. 
When C. albicans isolate #1 was tested in RPMI media, CoD had MIC values between 
0.977 and 1.9531 µg/mL while the copper dimer’s MIC was between 31.25 and 62.5 µg/mL 
(Table 1). Based on the relative MIC values, C. albicans isolate #1 is 32-64 times more sensitive 
to CoD than to CuD. When the KC643 WT (wildtype for the KC6 and KC7 crp1Δ mutants) was 
tested in the same conditions, CoD demonstrated 32 to 128 times more activity than CuD with an 
MIC range of 0.244 to 0.488 µg/mL for the CoD and 15.625 to 32.25 µg/mL for the CuD. The 
maximum fluconazole control (maximally at 6.4 µg/mL) was found to be at 0.8 µg/mL for both 
wildtype strains 
C. albicans isolate #1 and KC643 WT were also tested in minimal YPD (lacking uridine) 
media using the same assay procedures (Table 2). The results show that the yeast organisms 
demonstrated higher tolerance towards CuD (MIC at 125-250 µg/mL) than towards CoD (MIC at 
62.5 µg/mL). The MIC for the fluconazole control was 0.8 µg/mL. Interestingly, these strains 
showed significantly enhanced growth in the minimal YPD media than in RPMI (Table 2 and 3). 
The KC24 cup1Δ/ crp1Δ double gene knock-out mutant was tested in both RPMI and 
minimal YPD media. In RPMI media, the cup1Δ/ crp1Δ mutant showed higher sensitivity 
towards CuD than towards the CoD analogue (0.488 µg/mL and 3.125 µg/mL, respectively). 
This was expected because the cup1Δ/ crp1Δ mutant lacked the caCRP1 and caCUP1 genes that 
encode for the copper resistant mechanisms, metallothionein and P-type ATPase transporter 
protein. This trend of decreased copper sensitivity is also seen when the cup1Δ/ crp1Δ mutant 
was assayed in minimal YPD media. As was the case with wildtype KC643 and isolate #1, there 
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was significantly more growth in YPD media than in RPMI with the fluconazole showing an 
MIC value at 0.8 µg/mL instead of the 0.1 µg/mL in RPMI.  
 
 
 
Organism Isolate Fluconazole (µg/mL) CoD (µg/mL) CuD (µg/mL) Inoculum (10^3) 
S. cerevisiae   0.4 3.906 1.953 4.95 
S. cerevisiae   0.2 3.906 1.953 5.8 
S. cerevisiae    0.8 3.906 1.953 5.1 
Organism Isolate Fluconazole (µg/ mL) CoD  (µg/ mL) CuD (µg/ mL) Inoculum (103) 
C. albicans 1 0.1 0.977 31.25 4.8 
C. albicans 1 0.1 1.953 62.5 7.95 
C. albicans 1 0.1 0.977 62.5 3 
C. albicans 1 0.1 0.977 31.25 0.3 
C. albicans 1 0.025 0.977 62.5 0.35 
C. albicans KC643 WT 0.05 1.953 15.625 0.1 
C. albicans KC643 WT 0.05 0.244 31.25 0.15 
C. albicans cup1Δ/ crp1Δ 0.1 3.125 0.488 0.5 
C. albicans cup1Δ/ crp1Δ 0.1 0.244 0.977 0.15 
C. albicans ATCC 90028 0.2 4.883 15.625 2.2 
Organism Isolate (-) Fluconazole (µg/ mL) CoD  (µg/ mL) CuD (µg/ mL) Inoculum (103) 
C. albicans  1 0.8/04 62.5 250 3.65 
C. albicans  KC643 WT 0.8 62.5 62.5 0.9 
C. albicans  KC643 WT 0.8 62.5 250 0.3 
C. albicans  KC643 WT 0.8 62.5 125 3.6 
C. albicans  KC643 WT 0.8 62.5 125 1.85 
C. albicans KC643 WT 0.8 (+) 31.25 2.6 
C. albicans KC643 WT 0.8 (+) 125 2.25 
C. albicans KC6  crp1Δ 0.8 (+) 62.5 21 
C. albicans KC7  crp1Δ 0.8 (+) 62.5 1.55 
C. albicans  cup1Δ/ crp1Δ  0.8 31.25 15.625 2.4 
C. albicans  cup1Δ/ crp1Δ 0.8 125 15.625 2.5 
Organism Isolate (+) Fluconazole (µg/ mL) CoD  (µg/ mL) CuD (µg/ mL) Inoculum (103) 
C. albicans KC12 WT 0.8 (+) 31.25 TBD 
C. albicans KC2  cup1Δ 0.8 (+) 31.25  TBD 
Table 2. MIC values of C. albicans isolates in RMPI-MOPS 
Table 3. MIC values of C. albicans isolates in YPD (+)/(-) Uridine as indicated. 
Table 1. MIC values of S. cerevisiae isolates in MHB 
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Conclusion 
Resistance to fluconazole by Candida albicans is a major issue for patients undergoing 
long term treatment. C. albicans, as an opportunistic organism, provides several methods of 
mutagenesis and offers great promise in deepening our understanding this yeast’s resistance. The 
mutant strains that we used had homozygous URA3 disruptions. The URA3 disruption was 
created by genetically transforming and selectively complimenting a gal1 mutation. The 
subsequent recombination with a CAT sequence led GAL1 and one CAT copy to be excised.[13] 
The mutant strains we used contained had the deletion and complementation of this 
URA3 disruption, making the organisms dependent on outside sources of uridine, and were used 
as quality control constructs. The wildtype KC2 (wildtype for mutants lacking the CaCUP1, 
“cup1Δ”) lack the URA3 gene while the wildtype KC643 (wildtype for mutants lacking the 
CaCRP1 gene, “crp1 Δ”) had the URA3 disrupted and recomplemented to ensure that the URA3 
disruption itself did not have any effect on cell growth.[13] 
Aside from fluconazole, studies by Kornitzer et al. have found that Candida albicans 
demonstrated increased resistance against copper(II) metal. The CaCUP1 gene sequence is 
identical to the protein sequence of C. albicans copper binding metallothionein and thus works 
by chelating intracellular copper ions. The CaCRP1 gene has all the signature domains of copper 
transporting ATPases, functions catalytically, and is therefore thought to play a more active role 
in copper resistance. Of the two main copper mediators, CaCRP1 acts by effluxing copper while 
the CaCUP1 functions stoichiometrically.[1] 
 MIC values obtained for the two wildtype strains and the Candida albicans isolate #1 
shows that the CoD complex was consistently 32 to 62 times lower than the MIC values required 
of the CuD. The KC643 WT also demonstrated marked sensitivity towards CoD with MIC 32 to 
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132 times lower than the MIC values of CuD. Additionally, the double knockout mutants 
(“cup1Δ /crp1Δ”) showed greater sensitivity towards the copper analogue than towards the 
cobalt complex. This further suggested that CaCRP1 and/or CaCUP1 were responsible for the 
higher resistance in the WT strains. However, according to table 3, CuD was more active in 
cup1Δ /crp1Δ than in crp1Δ and cup1Δ alone. This suggests that metallothionein and the copper 
extrusion pump are working together to reduce intracellular copper concentrations. 
 When in vitro assays were performed in YPD, overall increased growth of all the strains 
was observed, especially in Candia albicans isolate #1 and the two wildtype strains. In these 
three strains, higher MIC values were observed for CuD than for CoD, as expected, because all 
three strains should still contain their copper resistance proteins. When comparing the growth 
rates of the cup1Δ and crp1Δ mutants, it was found that the strains missing the CaCRP1 gene 
was consistently more susceptible to the Cu(II) complex than to the CoD analogue. Additionally, 
CuD was more active than CoD was in the cup1Δ /crp1Δ mutant. This suggests that both genes 
function together for a greater total sum of copper resistance.  
 Another interesting observation is the lowered activity of CoD when in vitro assays were 
performed in YPD media. The maximum CoD dimer solutions that were used contained both 
25% and 2.5% methanol concentrations (drug vehicle control). Slight growth inhibition was 
observed in 25% methanol, but the MIC values were comparable with those of the methanol 
control that was also tested (data not shown) and no growth inhibition was seen in 2.5% 
methanol. This observation is different from that seen when in vitro assays were performed in 
RPMI media in which the CoD demonstrated substantially lower  MIC values than its methanol 
control. Along with decreased susceptibility towards CoD, the C. albicans strains also 
29 
 
demonstrated lower MIC values for CuD, indicating a lower sensitivity to both CoD and CuD in 
YPD media.  
 A possible explanation for the lowered susceptibility towards CuD and CoD in YPD 
media could be that YPD contains metal chelators that in turn allows Candida albicans to grow.  
This chelator effect is not observed in RPMI media or in MHB. 
 The MIC values observed for S. cerevisiae showed that the yeast is slightly more 
sensitive to CuD than to CoD. Additionally, S. cerevisiae is more susceptible to CuD than was C. 
albicans in RPMI assays. This observation aligned with our expectations because S. cerevisiae 
possess two copper import transporters, Ctr1 and Ctr3. It is also possible that the actual substrate 
for these transporters is Cu(I), suggesting that and Cu(II) is therefore reduced in the process. 
 Candida albicans contains a copper detoxification mechanism through an extensive 
copper extrusion pump. However, at high copper concentrations, copper catalyzes reactive 
oxygen species and is especially toxic in anaerobic conditions (such as in the digestive tract). 
Therefore, in eukaryotes, intracellular copper concentration must be maintained through 
controlling copper influx and the synthesis of copper chelators such as metallothionein.  
 It is likely that C. albicans’s ecological niche has led it to develop a dedicated resistant 
mechanism. Candida albicans thrives in the digestive tract which contains the highest 
concentration of copper. It was also found that copper becomes even more toxic in anaerobic 
conditions, which is the case in the digestive tract. As a result, copper extruding pumps may have 
developed through evolution to let Candida albicans survive in its environment. Acting alone, 
the metallothionein would be unable to handle the amount of entering copper, leading to the 
shutdown of the system. Therefore, Candida albicans likely adapted by developing a second 
mechanism to pump out a continuous influx of copper: the P-type ATPases extrusion pump.[1] 
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 The observations of C. albicans growth in RPMI suggest that C. albicans does not have 
similar resistance mechanisms for cobalt as it does for copper. In vitro assays of the Kornitzer 
strains were discontinued in RPMI because minimal growth was seen all the microtiter plate 
wells. However, observations of C. albicans in YPD media follows our expectations that the 
mutant strains are more susceptible to copper due to the absence of a copper extrusion pump 
and/or the copper binding protein, metallothionein.  
 Routes of investigation for the near future would be completing in vitro assays of all 
strains as well as performing in vitro assays in MHB to determine if YPD contain metal binders. 
Additionally, inductively coupled plasma atomic emission spectroscopy (ICP-AES) will be 
performed to determine the metal retention time in all seven isolates of C. albicans. 
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